Can insulin resistance and hyperinsulinemia contribute to prostate growth and urinary symptoms?

Insulin resistance and compensatory hyperinsulinemia are biologically plausible contributors to prostate growth signaling and are moderately supported correlates of larger prostate volume and more severe male LUTS. The evidence supports association rather than proof of causation or a reliable predictor of clinical progression.

Clinical and observational evidence

• Higher HOMA-IR has been independently associated with larger prostate volume in older men. In one prospective cohort, men with fasting insulin >13 mU/L versus <7 mU/L had mean prostate volumes of 61 versus 45 mL and annual growth of 1.49 versus 0.84 mL/year.
• Associations are not uniform: adjusted analyses in the Flint Men’s Health Study found no relationship between hyperinsulinemia/insulin resistance and BPH burden or progression, and REDUCE did not show HOMA-IR predicted four-year volume change.
• In 544 men, insulin resistance was independently associated with severe LUTS (adjusted OR 2.00, 95% CI 1.20–3.34), including higher storage and voiding symptom scores. This does not establish that insulin resistance causes symptoms, which may also reflect bladder, vascular, neurologic, or polyuric effects of metabolic disease.

Mechanistic rationale

• Insulin- and IGF-1-receptor activation engages PI3K–AKT–mTOR and RAS–RAF–MEK–ERK/MAPK pathways, supporting cell-cycle progression, growth, and survival.
• Prostate models show stromal IGF-1 can drive epithelial proliferation through increased MAPK, AKT, and cyclin D and reduced p27. Human BPH tissue studies similarly link larger glands with higher insulin-receptor/IGF-1/IGF-2 expression and lower IGFBP-3, potentially increasing IGF bioavailability.

Clinical implications

• At age 77, LUTS assessment should not assume prostatic obstruction: diabetes-related glycosuria/polyuria, medications, vascular disease, and bladder dysfunction can contribute.
• Metabolic risk management—physical activity, weight reduction where appropriate, and diabetes/metabolic-syndrome care—remains relevant alongside standard LUTS/BPH evaluation.

Bottom line

• Insulin resistance/hyperinsulinemia likely contribute to a growth-permissive insulin–IGF signaling environment and are associated with prostate enlargement and LUTS, but they are not established as direct causes of either condition.